Title: Treatments for Diabetic Macular Edema: Past, Present, and Future
Abstract: Practical RetinaTreatments for Diabetic Macular Edema: Past, Present, and Future Michael E. Jansen, MD, , , MD Seenu M. Hariprasad, MD, , , and , MD Michael A. Singer, MD, , MD Michael E. Jansen, MD , Seenu M. Hariprasad, MD , and Michael A. Singer, MD Ophthalmic Surgery, Lasers and Imaging Retina, 2016;47(9):794–800Published Online:September 01, 2016https://doi.org/10.3928/23258160-20160901-01Cited by:6PDFView Full Text ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinkedInRedditEmail SectionsMore1.Moss SE, Klein R, Klein BE. The 14-year incidence of visual loss in a diabetic population. Ophthalmology. 1998; 105(6):998–1003.10.1016/S0161-6420(98)96025-0 Crossref MedlineGoogle Scholar2.No authors listed. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol. 1985; 103(12):1796–1806.10.1001/archopht.1985.01050120030015 Crossref MedlineGoogle Scholar3.Diabetic Retinopathy Clinical Research NetworkElman MJ, Aiello LP, et al.Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010; 117(6):1064–1077.10.1016/j.ophtha.2010.02.031 Crossref MedlineGoogle Scholar4.Nguyen QD, Brown DM, Marcus DM, et al.Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012; 119(4):789–801.10.1016/j.ophtha.2011.12.039 Crossref MedlineGoogle Scholar5.Rajendram R, Fraser-Bell S, Kaines A, et al.A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol. 2012; 130(8):972–979.10.1001/archophthalmol.2012.393 Crossref MedlineGoogle Scholar6.Brown DM, Schmidt-Erfurth U, Do DV, et al.Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. Ophthalmology. 2015; 122(10):2044–52.10.1016/j.ophtha.2015.06.017 Crossref MedlineGoogle Scholar7.Dugel P. EARLY: Anti-VEGF treatment response at week 12 and long term outcomes in DME. Paper presented at the American Academy of Ophthalmology Retina Subspecialty Day; November 13–17, 2015; Las Vegas, NV. Google Scholar8.Gonzales V, Augustin A, Campbell J, et al.EARLY: Anti-VEGF treatment response at week 12 and long term outcomes in DME. Paper presented at World Ophthalmology Congress; February 5–9, 2016; Guadalajara, Mexico. Google Scholar9.Boyer DS, Yoon YH, Belfort R, et al.Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014; 121(10):1904–1914.10.1016/j.ophtha.2014.04.024 Crossref MedlineGoogle Scholar10.Campochiaro PA, Brown DM, Pearson A, et al.Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology. 2012; 119(10):2125–2132.10.1016/j.ophtha.2012.04.030 Crossref MedlineGoogle Scholar11.Bressler SB, Qin H, Beck RW, et al.Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab. Arch Ophthalmol. 2012; 130(9):1153–1161.10.1001/archophthalmol.2012.1107 Crossref MedlineGoogle Scholar12.Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology. 2008; 115(9):1447–1459.10.1016/j.ophtha.2008.06.015 Crossref MedlineGoogle Scholar13.Maturi RK, Bleau L, Saunders J, Mubasher M, Stewart MW. A 12-month, single-masked, randomized controlled study of eyes with persistent diabetic macular edema after multiple anti-vegf injections to assess the efficacy of the dexamethasone-delayed delayed system as an adjunct to bevacizumab compared with continued bevacizumab monotherapy. Retina. 2015; 35(8):1604–1614.10.1097/IAE.0000000000000533 Crossref MedlineGoogle Scholar14.Figueira J, et al.RESPOND study: Interim six month results. Presented at the 2015 EURETINA Congress; September 17–20, 2015; Nice, France. Google Scholar15.Campochiaro PA. Results of the AKB-9778 in the treatment of Diabetic retinopathy: Results from the TIME-2 Study. Presented at Subspecialty Day, American Academy of Ophthalmology; November 2015, Las Vegas, NV. Google Scholar16.Singer MA. Results of the Optimeyes phase 2 study. Presented at World of Ophthalmology Congress; February 2016; Guadalajara, Mexico. Google Scholar17.A phase 2, double-masked, randomized, active controlled study to evaluate the efficacy and safety of ASP8232 in reducing central retinal thickness in subjects with diabetic macular edema. ClinicalTrials.gov identifier: NCT02302079. Google Scholar18.A phase 2 randomized, controlled, double-masked, multicenter clinical trial designed to evaluate the safety and exploratory efficacy of Luminate (ALG-1001) as compared to Avastin and focal laser photocoagulation in the treatment of diabetic macular edema. ClinicalTrials.gov identifier: NCT02348918. Google Scholar19.Anti-vascular endothelial growth factor plus anti-angiopoietin 2 in fixed combination therapy: evaluation for the treatment of diabetic macular edema (RUBY). ClinicalTrials.gov identifier: NCT02712008. Google Scholar Next article FiguresReferencesRelatedDetailsCited by Adams O, Schechet S and Hariprasad S (2020) Discontinuous to continuous therapy for persistent diabetic macular edema leads to reduction in treatment frequency, European Journal of Ophthalmology, 10.1177/1120672120901691, 31:2, (612-619), Online publication date: 1-Mar-2021. Al-khersan H, Hariprasad S, Singh S and Chhablani J (2019) Long-term outcomes after intravitreal dexamethasone treatment in steroid responders, Acta Diabetologica, 10.1007/s00592-019-01299-5, 56:6, (675-680), Online publication date: 1-Jun-2019. Schechet S, Adams O, Eichenbaum D and Hariprasad S (2019) Macular thickness amplitude changes when switching from discontinuous to continuous therapy for diabetic macular oedema, BMJ Open Ophthalmology, 10.1136/bmjophth-2019-000271, 4:1, (e000271), Online publication date: 1-Mar-2019. Al-khersan H, Hariprasad S, Chhablani J, Al-khersan H, Hariprasad S, Chhablani J, Agarwal K, Ansari W, Agrawal K, Arevalo J, Banker A, Farah M, Goel N, Gupta V, Jain N, Lanzetta P, Loewenstein A, Mehrotra N, Modi A, Nagpal M, Rosenblatt A, Sarao V, Sarvaiya C, Singh R, Veritti D and Yadav N (2017) Early Response to Intravitreal Dexamethasone Implant Therapy in Diabetic Macular Edema May Predict Visual Outcome, American Journal of Ophthalmology, 10.1016/j.ajo.2017.10.004, 184, (121-128), Online publication date: 1-Dec-2017. Pinto M, Mathis T, Massin P, Akesbi J, Lereuil T, Voirin N, Matonti F, Fajnkuchen F, Conrath J, Milazzo S, Korobelnik J, Baillif S, Denis P, Creuzot-Garcher C, Srour M, Dupas B, Sudhalkar A, Bilgic A, Tadayoni R, Souied E, Dot C and Kodjikian L (2021) Visual Acuity Gain Profiles and Anatomical Prognosis Factors in Patients with Drug-Naive Diabetic Macular Edema Treated with Dexamethasone Implant: The NAVEDEX Study, Pharmaceutics, 10.3390/pharmaceutics13020194, 13:2, (194) Al-khersan H, Venincasa M, Kloosterboer A, Sridhar J, Smiddy W, Townsend J and Flynn H (2020) Pars Plana Vitrectomy Reoperations for Complications of Proliferative Diabetic Retinopathy, Clinical Ophthalmology, 10.2147/OPTH.S252285, Volume 14, (1559-1563) Request Permissions InformationCopyright 2016, SLACK IncorporatedPDF downloadMichael E. Jansen, MD, can be reached at University of Texas Health Science Center San Antonio, 7703 Floyd Curl Drive, MSC 6230, San Antonio, TX 78229; email: [email protected]com.Seenu M. Hariprasad, MD, can be reached at the Department of Ophthalmology and Visual Science, University of Chicago, 5841 S. Maryland Avenue, MC2114, Chicago, IL 60637; email: [email protected]edu.Michael A. Singer, MD, can be reached at Medical Center Ophthalmology Associates, 9157 Huebner Road, San Antonio, TX 78240; email: [email protected]com.Disclosures: Dr. Singer has received consulting, speaker, and research fees from Allergan, Genentech, Aerpio, and Ampio; speaker and research fees from Regeneron; and research fees from Aestellis and Allegro. Dr. Hariprasad is a consultant for Alcon, Allergan, Bayer, OD-OS, Optos, Clearside Biomedical, Ocular Therapeutix, Janssen, Leica, Spark, and Regeneron. Dr. Jansen has no relevant financial disclosures.Authors' Note:Special thanks to Daniel Kermany for his invaluable assistance in the preparation of this article.
Publication Year: 2016
Publication Date: 2016-09-01
Language: en
Type: review
Indexed In: ['crossref', 'pubmed']
Access and Citation
Cited By Count: 7
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot